Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

GOVX

Geovax Labs Inc

Last Close
Jun 18 • 04:00PM ET
1.90
Dollar change
+0.79
Percentage change
71.17 		%
Held by: VXF Scroll to Statements
Index- P/E- EPS (ttm)-14.45 Insider Own1.45% Shs Outstand2.53M Perf Week22.58%
Market Cap4.81M Forward P/E- EPS next Y-1.76 Insider Trans92.96% Shs Float2.49M Perf Month11.76%
Income-27.78M PEG- EPS next Q-4.43 Inst Own9.52% Short Float1.80% Perf Quarter-5.47%
Sales0.00M P/S- EPS this Y38.98% Inst Trans- Short Ratio0.43 Perf Half Y-59.90%
Book/sh0.02 P/B80.82 EPS next Y79.82% ROA-180.60% Short Interest0.04M Perf Year-79.50%
Cash/sh0.30 P/C6.24 EPS next 5Y- ROE-242.41% 52W Range1.10 - 10.24 Perf YTD-64.91%
Dividend Est.- P/FCF- EPS past 5Y92.12% ROI-51181.90% 52W High-81.45% Beta2.93
Dividend TTM- Quick Ratio0.87 Sales past 5Y-20.34% Gross Margin- 52W Low72.73% ATR (14)0.27
Dividend Ex-Date- Current Ratio0.87 EPS Y/Y TTM-37.03% Oper. Margin0.00% RSI (14)58.90 Volatility34.89% 18.70%
Employees17 Debt/Eq0.00 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price7.00
Option/ShortNo / No LT Debt/Eq0.00 EPS Q/Q-7.47% Payout- Rel Volume303.37 Prev Close1.11
Sales Surprise- EPS Surprise55.58% Sales Q/Q- EarningsMay 14 AMC Avg Volume103.94K Price1.90
SMA2016.84% SMA5017.45% SMA200-57.48% Trades Volume31,532,229 Change71.17%
Date Action Analyst Rating Change Price Target Change
Nov-19-20Initiated Maxim Group Buy $8
Jun-18-24 07:00AM
GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1
(NewMediaWire) +71.17%
Jun-07-24 07:22AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
(InvestorPlace) -6.40%
May-29-24 09:00AM
GeoVax to Present at BIO International Convention 2024
(NewMediaWire) +7.98%
May-17-24 08:00AM
GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market
(NewMediaWire)
May-15-24 08:19AM
GeoVax Labs, Inc. (NASDAQ:GOVX) Q1 2024 Earnings Call Transcript
(Insider Monkey)
07:53AM
GOVX Stock Earnings: Geovax Labs Beats EPS for Q1 2024
(InvestorPlace)
May-14-24 04:00PM
GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update
(NewMediaWire)
May-07-24 09:00AM
GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
(NewMediaWire)
Apr-04-24 12:30PM
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
(GlobeNewswire)
Mar-28-24 09:00AM
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
(GlobeNewswire) +8.11%
Mar-12-24 09:00AM
GeoVax to Present at the 36th Annual Roth Conference
(GlobeNewswire)
Mar-06-24 09:00AM
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
(GlobeNewswire)
Mar-02-24 08:45AM
GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Feb-29-24 04:00PM
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
(GlobeNewswire)
Feb-22-24 09:00AM
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
(GlobeNewswire)
Feb-19-24 09:00AM
GeoVax to Present at the 2024 BIO CEO & Investor Conference
(GlobeNewswire)
Feb-13-24 09:00AM
GeoVax Announces Multiple Patent Issuances and Allowances
(GlobeNewswire)
Feb-06-24 09:00AM
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
(GlobeNewswire)
Jan-29-24 09:00AM
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
(GlobeNewswire) -8.25%
Jan-08-24 09:00AM
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
(GlobeNewswire)
Jan-04-24 09:00AM
GeoVax Announces Gedeptin Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
(GlobeNewswire)
Jan-03-24 09:00AM
GeoVax Announces Issuance of Malaria Vaccine Patent
(GlobeNewswire)
Dec-27-23 09:00AM
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024
(GlobeNewswire)
Dec-19-23 09:00AM
GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
(GlobeNewswire)
Dec-06-23 07:00AM
Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now
(GlobeNewswire)
Dec-05-23 07:00AM
Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now
(GlobeNewswire)
Nov-30-23 04:30PM
GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress
(GlobeNewswire)
Nov-29-23 09:00AM
GeoVax to Participate in Upcoming December Investor Events
(GlobeNewswire)
Nov-28-23 09:00AM
GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress
(GlobeNewswire)
Nov-14-23 09:00AM
Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
(GlobeNewswire)
Nov-10-23 10:24AM
GeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-08-23 04:00PM
GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire)
Nov-01-23 07:00AM
Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now
(GlobeNewswire)
Oct-31-23 09:00AM
GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023
(GlobeNewswire)
07:00AM
Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now
(GlobeNewswire)
Oct-30-23 09:00AM
GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine
(GlobeNewswire)
Oct-25-23 09:00AM
GeoVax to Participate in Upcoming November Investor and Industry Events
(GlobeNewswire)
Oct-24-23 09:00AM
GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities
(GlobeNewswire)
Oct-09-23 09:00AM
GeoVax Receives Notice of Allowance for Marburg Vaccine Patent
(GlobeNewswire)
Oct-05-23 09:00AM
GeoVax Receives Notice of Allowance for HIV Vaccine Patent
(GlobeNewswire) +5.54%
Oct-04-23 07:00AM
Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now
(GlobeNewswire) -5.81%
Oct-03-23 07:00AM
Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now
(GlobeNewswire)
Sep-27-23 09:00AM
GeoVax to Participate in Upcoming October Investor and Industry Events
(GlobeNewswire)
Sep-26-23 09:00AM
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
(GlobeNewswire)
Sep-21-23 09:35AM
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
(GlobeNewswire)
Sep-20-23 09:00AM
GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference
(GlobeNewswire)
Sep-19-23 09:00AM
GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients
(GlobeNewswire)
Sep-12-23 09:00AM
GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference
(GlobeNewswire)
Sep-11-23 09:00AM
GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster
(GlobeNewswire)
Aug-31-23 09:00AM
GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
(GlobeNewswire) -5.02%
Aug-29-23 09:00AM
GeoVax to Present at the Emerging Growth Conference on September 6, 2023
(GlobeNewswire)
Aug-28-23 09:00AM
GeoVax Receives Notice of Allowance for Malaria Vaccine Patent
(GlobeNewswire)
Aug-11-23 12:47PM
GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2023 Earnings Call Transcript
(Insider Monkey)
Aug-10-23 09:00AM
GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
(GlobeNewswire)
Aug-09-23 04:00PM
GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update
(GlobeNewswire)
Jul-26-23 09:00AM
GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023
(GlobeNewswire) +11.62%
Jul-24-23 09:00AM
GeoVax Announces Issuance of Ebola Vaccine Patent
(GlobeNewswire)
Jul-20-23 09:00AM
GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
(GlobeNewswire)
Jul-10-23 09:00AM
GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference
(GlobeNewswire)
Jun-28-23 09:00AM
GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference
(GlobeNewswire)
Jun-27-23 10:15AM
GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights
(GlobeNewswire)
May-31-23 09:00AM
GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates
(GlobeNewswire)
May-25-23 09:00AM
GeoVax to Participate in Upcoming Industry Meetings
(GlobeNewswire) -10.67%
May-24-23 04:32PM
GeoVax's Next-Gen Single Dose COVID-19 Vaccine Shows Promising Results
(Benzinga) +14.17%
08:00AM
GeoVaxs Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients
(GlobeNewswire)
May-15-23 09:00AM
GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings
(GlobeNewswire)
May-09-23 09:00AM
GeoVax Labs to Participate in A.G.P.s Virtual Healthcare Conference
(GlobeNewswire)
May-04-23 04:00PM
GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update
(GlobeNewswire) +8.15%
Apr-26-23 09:00AM
GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host
(GlobeNewswire)
Apr-25-23 09:00AM
GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023
(GlobeNewswire)
Apr-17-23 09:00AM
GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses
(GlobeNewswire)
Apr-06-23 10:00AM
GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate
(GlobeNewswire)
Apr-05-23 01:30PM
GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress
(GlobeNewswire)
Mar-30-23 11:00AM
GeoVax to Participate at the World Vaccine Congress with Multiple Presentations
(GlobeNewswire)
Mar-27-23 07:08AM
GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2022 Earnings Call Transcript
(Insider Monkey) -6.22%
Mar-23-23 04:00PM
GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update
(GlobeNewswire) -6.20%
Mar-15-23 09:00AM
GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress
(GlobeNewswire)
Mar-09-23 09:00AM
GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update
(GlobeNewswire)
Mar-06-23 09:00AM
GeoVax to Participate at the 35th Annual Roth Conference
(GlobeNewswire) -6.64%
Feb-27-23 09:00AM
GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections
(GlobeNewswire) -8.27%
Feb-15-23 09:00AM
GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial
(GlobeNewswire)
Feb-08-23 09:00AM
GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines
(GlobeNewswire)
Feb-07-23 09:00AM
GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers
(GlobeNewswire)
Jan-26-23 09:00AM
GeoVax to Present at the 2023 BIO CEO & Investor Conference
(GlobeNewswire) -32.33%
Jan-25-23 11:00AM
GeoVax Receives Notice of Allowance for Zika Vaccine Patent
(GlobeNewswire) +58.89%
Jan-04-23 09:00AM
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023
(GlobeNewswire)
Dec-20-22 09:00AM
Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax
(GlobeNewswire)
Dec-07-22 04:00PM
GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors
(GlobeNewswire)
Nov-28-22 10:15AM
GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022
(GlobeNewswire)
Nov-11-22 05:46AM
GeoVax Labs Third Quarter 2022 Earnings: US$0.17 loss per share (vs US$0.31 loss in 3Q 2021)
(Simply Wall St.) +7.50%
Nov-09-22 04:00PM
GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update
(GlobeNewswire) -8.77%
Oct-31-22 10:33AM
Will GeoVax Labs (NASDAQ:GOVX) Spend Its Cash Wisely?
(Simply Wall St.)
Oct-26-22 09:00AM
GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022
(GlobeNewswire) +27.02%
Oct-11-22 09:00AM
GeoVax to Present at Vaccines Summit-2022
(GlobeNewswire)
Oct-06-22 09:00AM
GeoVax to Present at Upcoming Investor Conferences
(GlobeNewswire)
Sep-07-22 09:00AM
GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference
(GlobeNewswire)
Sep-01-22 09:00AM
GeoVax Announces Addition to Its Board of Directors
(GlobeNewswire)
Aug-18-22 10:27AM
GeoVax Labs Stock Is a Monkeypox Meme Play for Bold Traders
(InvestorPlace) -12.83%
Aug-17-22 09:29AM
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
(InvestorPlace)
Aug-10-22 09:13AM
10 Healthcare and Biotech Stocks to Buy Amid Monkeypox Threat
(Insider Monkey)
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DODD DAVID APresident, CEOFeb 22 '24Buy2.278,20918,66318,661Feb 22 04:41 PM
DODD DAVID APresident, CEOFeb 21 '24Buy2.155201,11810,452Feb 22 04:41 PM
Reynolds MarkCFOFeb 07 '24Buy2.772,0005,5407,213Feb 07 04:43 PM
McKee Kelly T. Jr.Chief Medical OfficerDec 22 '23Buy0.366,9442,50035,782Dec 26 03:51 PM
McKee Kelly T. Jr.Chief Medical OfficerSep 25 '23Buy0.529,6535,02028,838Sep 27 04:33 PM
DODD DAVID APresident, CEOAug 25 '23Buy0.5735,08720,000148,957Aug 28 04:05 PM
Reynolds MarkCFOAug 18 '23Buy0.5210,0005,17978,184Aug 21 08:39 AM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • careers • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.